A recent Financial Times article reports that the company behind the “Enhanced Games” plans to begin selling injectable peptides amid signals of potential deregulation from U.S. Health Secretary Robert F. Kennedy Jr. The move reflects growing interest in peptides, despite ongoing safety concerns and limited clinical evidence, as companies position themselves to enter the evolving consumer health market.
In the article, Frier Levitt partner Edgar J. Asebey notes that the industry is already reacting quickly to these developments, with companies racing to capitalize on potential regulatory changes. Businesses are eager to be first to market, signaling a rapidly evolving and highly competitive landscape. Asebey’s insight highlights the legal and regulatory uncertainty surrounding peptides and underscores the importance of careful navigation as companies explore opportunities in this emerging space.
Read the full article with Financial Times (subscription required).
